2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemic
2014
The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa
Pretorius C, Menzies NA, Chindelevitch L, Cohen T, Cori A, Eaton JW, Fraser C, Gopalappa C, Hallett TB, Salomon JA, Stover J, White RG, Dodd PJ. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa. AIDS 2014, 28: s25-s34. PMID: 24468944, DOI: 10.1097/qad.0000000000000085.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyTB incidenceART expansionHIV treatment policyHIV-positive individualsART eligibility criteriaTuberculosis outcomesART eligibilitySurvival benefitTB burdenTB casesHIV transmissionART coverageHIV treatmentHIV epidemicMortality reductionPositive individualsEligibility criteriaTreatment policyART servicesTuberculosisIncidenceCurrent eligibilityIndependent mathematical modelsRecent findings